Eli Lilly Reports Stellar First Quarter Performance

Eli Lilly announced a remarkable 45% increase in first-quarter revenue for fiscal 2025, reaching $12.73 billion. This surge was primarily driven by the exceptional volume growth of its flagship products, Mounjaro and Zepbound.

Financial Highlights and Future Outlook

The company's net income for the quarter stood at $2.76 billion, marking a 23% year-over-year growth. Earnings per share were reported at $3.06, even after accounting for $1.57 billion in acquired in-process R&D charges.

CEO David Ricks emphasized the promising progress of forgilzumab, the company's oral GLP-1 candidate, and reiterated the annual revenue guidance of $58 billion to $61 billion. Additionally, Eli Lilly unveiled ambitious plans for a $50 billion expansion in US manufacturing capacity to cater to the escalating demand.